A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus Caspofungin Followed by Voriconazole in the Treatment of Candidemia and Other Invasive Candida Infections

Trial Profile

A Phase III, Double-blind, Randomized Study to Evaluate the Safety and Efficacy of BAL8557 Versus Caspofungin Followed by Voriconazole in the Treatment of Candidemia and Other Invasive Candida Infections

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Isavuconazole (Primary) ; Isavuconazole (Primary) ; Isavuconazonium (Primary) ; Isavuconazonium (Primary) ; Caspofungin; Voriconazole
  • Indications Candidaemia; Candidiasis
  • Focus Registrational; Therapeutic Use
  • Acronyms ACTIVE
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 22 May 2017 Planned locations for this trial also included Colombia, Egypt, Netherlands, Poland, Turkey, UK.
    • 25 Apr 2017 Results assessing correlation between exposure measures and efficay outcomes presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases.
    • 25 Apr 2017 Results assessing efficacy in the subset of patients who switched from IV to oral therapy, presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top